These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 34328655)

  • 21. Dynamic incorporation of prior knowledge from multiple domains in biomarker discovery.
    Guan X; Runger G; Liu L
    BMC Bioinformatics; 2020 Mar; 21(Suppl 2):77. PubMed ID: 32164534
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bayesian two-step Lasso strategy for biomarker selection in personalized medicine development for time-to-event endpoints.
    Gu X; Yin G; Lee JJ
    Contemp Clin Trials; 2013 Nov; 36(2):642-50. PubMed ID: 24075829
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Bayesian additive decision trees of biomarker by treatment interactions for predictive biomarker detection and subgroup identification.
    Zhao Y; Zheng W; Zhuo DY; Lu Y; Ma X; Liu H; Zeng Z; Laird G
    J Biopharm Stat; 2018; 28(3):534-549. PubMed ID: 29020511
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiplicity issues in exploratory subgroup analysis.
    Lipkovich I; Dmitrienko A; Muysers C; Ratitch B
    J Biopharm Stat; 2018; 28(1):63-81. PubMed ID: 29173045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Towards precision medicine: Accurate predictive modeling of infectious complications in combat casualties.
    Dente CJ; Bradley M; Schobel S; Gaucher B; Buchman T; Kirk AD; Elster E
    J Trauma Acute Care Surg; 2017 Oct; 83(4):609-616. PubMed ID: 28538622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Controlled variable selection in Weibull mixture cure models for high-dimensional data.
    Fu H; Nicolet D; Mrózek K; Stone RM; Eisfeld AK; Byrd JC; Archer KJ
    Stat Med; 2022 Sep; 41(22):4340-4366. PubMed ID: 35792553
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Framework for personalized prediction of treatment response in relapsing remitting multiple sclerosis.
    Stühler E; Braune S; Lionetto F; Heer Y; Jules E; Westermann C; Bergmann A; van Hövell P;
    BMC Med Res Methodol; 2020 Feb; 20(1):24. PubMed ID: 32028898
    [TBL] [Abstract][Full Text] [Related]  

  • 28. IPAD: Stable Interpretable Forecasting with Knockoffs Inference.
    Fan Y; Lv J; Sharifvaghefi M; Uematsu Y
    J Am Stat Assoc; 2020; 115(532):1822-1834. PubMed ID: 33716359
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Feature set optimization in biomarker discovery from genome-scale data.
    Fortino V; Scala G; Greco D
    Bioinformatics; 2020 Jun; 36(11):3393-3400. PubMed ID: 32119073
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials.
    Lipkovich I; Dmitrienko A; B R
    Stat Med; 2017 Jan; 36(1):136-196. PubMed ID: 27488683
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Feature Selection Methods for Early Predictive Biomarker Discovery Using Untargeted Metabolomic Data.
    Grissa D; Pétéra M; Brandolini M; Napoli A; Comte B; Pujos-Guillot E
    Front Mol Biosci; 2016; 3():30. PubMed ID: 27458587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Competition-based control of the false discovery proportion.
    Luo D; Ebadi A; Emery K; He Y; Noble WS; Keich U
    Biometrics; 2023 Dec; 79(4):3472-3484. PubMed ID: 36652258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A simulation study on estimating biomarker-treatment interaction effects in randomized trials with prognostic variables.
    Haller B; Ulm K
    Trials; 2018 Feb; 19(1):128. PubMed ID: 29463271
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Auxiliary variable-enriched biomarker-stratified design.
    Wang T; Wang X; Zhou H; Cai J; George SL
    Stat Med; 2018 Dec; 37(30):4610-4635. PubMed ID: 30221368
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A flexible approach for predictive biomarker discovery.
    Boileau P; Qi NT; van der Laan MJ; Dudoit S; Leng N
    Biostatistics; 2023 Oct; 24(4):1085-1105. PubMed ID: 35861622
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bayesian personalized treatment selection strategies that integrate predictive with prognostic determinants.
    Ma J; Stingo FC; Hobbs BP
    Biom J; 2019 Jul; 61(4):902-917. PubMed ID: 30786040
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparison of approaches for combining predictive markers for personalised treatment recommendations.
    Pierce M; Emsley R
    Trials; 2021 Jan; 22(1):20. PubMed ID: 33407760
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Divining responder populations from survival data.
    Rahman R; Ventz S; Fell G; Vanderbeek AM; Trippa L; Alexander BM
    Ann Oncol; 2019 Jun; 30(6):1005-1013. PubMed ID: 30860592
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A general framework for subgroup detection via one-step value difference estimation.
    Johnson D; Lu W; Davidian M
    Biometrics; 2023 Sep; 79(3):2116-2126. PubMed ID: 35793474
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Subgroup identification for treatment selection in biomarker adaptive design.
    Lu TP; Chen JJ
    BMC Med Res Methodol; 2015 Dec; 15():105. PubMed ID: 26646831
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.